K
Kent Bondensgaard
Researcher at University of Southern Denmark
Publications - 10
Citations - 683
Kent Bondensgaard is an academic researcher from University of Southern Denmark. The author has contributed to research in topics: Locked nucleic acid & Nucleic acid. The author has an hindex of 5, co-authored 6 publications receiving 643 citations.
Papers
More filters
Journal ArticleDOI
Locked Nucleic Acid (LNA) Recognition of RNA: NMR Solution Structures of LNA:RNA Hybrids
TL;DR: It is suggested that the change in electronic density at the brim of the minor groove, introduced by the LNA modification, is causing an alteration of the pseudorotational profile of the 3'-flanking nucleotide, thus shifting this sugar equilibrium toward N-type conformation.
Journal ArticleDOI
The conformations of locked nucleic acids (LNA).
Michael B. Petersen,Christina B. Nielsen,Katrine E. Nielsen,Gitte A. Jensen,Kent Bondensgaard,Sanjay K. Singh,Vivek K. Rajwanshi,Alexei A. Koshkin,Britta M. Dahl,Jesper Wengel,Jens Peter Jacobsen +10 more
TL;DR: It is proposed that the exceptional stability of the LNA modified duplexes is caused by a quenching of concerted local backbone motions by the L NA nucleotides in ssLNA so as to decrease the entropy loss on duplex formation combined with a more efficient stacking of the nucleobases.
Journal ArticleDOI
Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity.
Kent Bondensgaard,Michael Nebeling Petersen,Sanjay K. Singh,Vivek K. Rajwanshi,Ravindra Kumar,Jesper Wengel,Jens Peter Jacobsen +6 more
TL;DR: Partly modified LNA:RNA duplexes may adopt a duplex structure between the standard A and B types, thereby making the RNA strand amenable to RNase H-mediated degradation.
Journal ArticleDOI
Blocking GM-CSF receptor α with mavrilimumab reduces infiltrating cells, pro-inflammatory markers and neoangiogenesis in ex vivo cultured arteries from patients with giant cell arteritis
Marc Corbera-Bellalta,Roser Alba-Rovira,Sujatha Muralidharan,Georgina Espígol-Frigolé,Roberto Ríos-Garcés,Javier Marco-Hernández,Amanda Denuc,Farah Kamberović,Patricia Pérez-Galán,Alexandra Joseph,Annalisa D'Andrea,Kent Bondensgaard,Maria C. Cid,John F. Paolini +13 more
TL;DR: The inhibitory effects of mavrilimumab on multiple steps in the GCA pathogenesis cascade in vitro are consistent with the clinical observation of reduced GCA flares in a phase 2 trial and support its development as a therapeutic option for patients with GCA.